KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Enterprise Value: 2011-2025

Historic Enterprise Value for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $2.4 billion.

  • Supernus Pharmaceuticals' Enterprise Value rose 82.40% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $958.8 million, marking a year-over-year increase of 130.93%. This contributed to the annual value of $1.5 billion for FY2024, which is 16.36% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Enterprise Value stood at $2.4 billion, which was up 93.09% from $1.2 billion recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Enterprise Value high stood at $2.4 billion for Q3 2025, and its period low was $973.5 million during Q3 2021.
  • Over the past 3 years, Supernus Pharmaceuticals' median Enterprise Value value was $1.4 billion (recorded in 2025), while the average stood at $1.5 billion.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Enterprise Value spiked by 82.73% in 2021, and later dropped by 24.40% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Enterprise Value (Quarterly) stood at $1.2 billion in 2021, then rose by 21.13% to $1.5 billion in 2022, then decreased by 9.59% to $1.3 billion in 2023, then rose by 16.36% to $1.5 billion in 2024, then skyrocketed by 82.40% to $2.4 billion in 2025.
  • Its last three reported values are $2.4 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.4 billion during Q1 2025.